{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:32:30Z","timestamp":1793431950678,"version":"4.5.0"},"reference-count":86,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Cancer immunotherapy is one of the most emerging and rapidly growing fields.<\/jats:p>\n            <jats:p>Ocular side effects associated with these therapies are common and can be present in up to 70% of patients.<\/jats:p>\n            <jats:p>The cornea may be involved in different pathogenic mechanisms triggered by different immunotherapeutic agents, and corneal disease varies from mild symptoms to severe corneal ulceration and melting with visual loss.<\/jats:p>\n            <jats:p>We aimed to review the incidence, mechanism, and management of ocular surface side effects in cancer patients receiving immunotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>With the recent use of immunotherapeutic agents in cancer patients, in particular immune checkpoint inhibitors (ICIs) and epidermal growth factor receptor (EGFR) inhibitors, ocular surface and corneal involvement are common side effects.<\/jats:p>\n            <jats:p>These patients can be at risk of sight threatening complications that warrant prompt diagnosis and careful monitoring and management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Immunotherapy- related corneal complications in cancer patients are associated with a decreased quality of life. Prompt recognition and an interdisciplinary approach between ophthalmologists and oncologists are crucial to handle immune related ocular adverse events in these patients, in order to maintain ocular surface integrity and avoid a vision threatening complication.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/aci.0000000000001007","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T17:00:10Z","timestamp":1720112410000},"page":"390-396","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Adverse effects of anti-cancer biologics on the ocular surface"],"prefix":"10.1097","volume":"24","author":[{"given":"Riham","family":"Shawer","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Hadassah-Hebrew University Medical Centre"},{"name":"St. John Eye Hospital, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Solomon","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hadassah-Hebrew University Medical Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"R1-20250527","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"R2-20250527","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2776(08)60930-X","article-title":"Immunologically privileged sites","volume":"25","author":"Barker","year":"1978","journal-title":"Adv Immunol"},{"key":"R3-20250527","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"R4-20250527","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"issue":"(S4)","key":"R5-20250527","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.13-S4-2","article-title":"The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation","volume":"13","author":"Wolchok","year":"2008","journal-title":"Oncologist"},{"key":"R6-20250527","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.2174\/1381612823666171004120152","article-title":"PD-1\/PD-L1 inhibitors for immuno-oncology: from antibodies to small molecules","volume":"23","author":"Geng","year":"2017","journal-title":"Curr Pharm Des"},{"key":"R7-20250527","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R8-20250527","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"key":"R9-20250527","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin oncol"},{"key":"R10-20250527","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"R11-20250527","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rehman","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"R12-20250527","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"R13-20250527","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"issue":"(Suppl 7)","key":"R14-20250527","doi-asserted-by":"crossref","first-page":"vii40","DOI":"10.1093\/rheumatology\/kez297","article-title":"Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy","volume":"58","author":"Abdel-Wahab","year":"2019","journal-title":"Rheumatology"},{"key":"R15-20250527","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.3390\/ijms21113962","article-title":"Immune checkpoints contribute corneal immune privilege: implications for dry eye associated with checkpoint inhibitors","volume":"21","author":"Hori","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R16-20250527","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/ICO.0000000000000724","article-title":"Cyclosporine for dry eye associated with nivolumab: a case progressing to corneal perforation","volume":"35","author":"Nguyen","year":"2016","journal-title":"Cornea"},{"key":"R17-20250527","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2796.2003.01074.x","article-title":"The cytokine network in sarcoidosis and its clinical relevance","volume":"253","author":"Ziegenhagen","year":"2003","journal-title":"J Intern Med"},{"key":"R18-20250527","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/CJI.0000000000000224","article-title":"Autoimmune granulomatous inflammation of lacrimal glands and axonal neuritis following treatment with ipilimumab and radiation therapy","volume":"41","author":"Dumbrava","year":"2018","journal-title":"J Immunother"},{"key":"R19-20250527","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/ICO.0000000000002460","article-title":"Nivolumab-induced ulcerative keratitis\u2014a case report","volume":"40","author":"Losonczy","year":"2021","journal-title":"Cornea"},{"key":"R20-20250527","first-page":"140","article-title":"Ipilimumab-induced ocular and orbital inflammation\u2014a case series and review of the literature","volume":"24","author":"Papavasileiou","year":"2016","journal-title":"Ocular Immunol Inflamm"},{"key":"R21-20250527","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/cxo.12973","article-title":"Corneal melting in a case undergoing treatment with pembrolizumab","volume":"103","author":"Weng","year":"2020","journal-title":"Clin Exp Optom"},{"key":"R22-20250527","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/ICO.0000000000002460","article-title":"Nivolumab-induced ulcerative keratitis\u2014a case report","volume":"40","author":"Losonczy","year":"2021","journal-title":"Cornea"},{"key":"R23-20250527","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMicm1910925","article-title":"Autoimmune keratitis after atezolizumab treatment","volume":"383","author":"Oh","year":"2020","journal-title":"N Engl J Med"},{"key":"R24-20250527","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000536103","article-title":"Bilateral paracentral corneal melting and left-eye perforation under tobemstomig novel treatment","volume":"15","author":"Gonz\u00e1lez de los M\u00e1rtires","year":"2024","journal-title":"Case Rep Ophthalmol"},{"key":"R25-20250527","doi-asserted-by":"crossref","first-page":"701951","DOI":"10.3389\/fimmu.2021.701951","article-title":"Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"R26-20250527","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.ophtha.2007.07.025","article-title":"Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases","volume":"115","author":"Miyazaki","year":"2008","journal-title":"Ophthalmology"},{"key":"R27-20250527","doi-asserted-by":"crossref","first-page":"101686","DOI":"10.1016\/j.ajoc.2022.101686","article-title":"Bilateral corneal perforation in Ipilimumab\/Nivolumab-associated peripheral ulcerative keratitis","volume":"28","author":"Aschauer","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R28-20250527","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/ICO.0000000000002490","article-title":"Bilateral corneal perforation in a patient under anti-PD1 therapy","volume":"40","author":"Ramaekers","year":"2021","journal-title":"Cornea"},{"key":"R29-20250527","doi-asserted-by":"crossref","first-page":"e940688","DOI":"10.12659\/AJCR.940688","article-title":"Corneal perforation in a patient treated with atezolizumab-bevacizumab combination therapy for unresectable hepatocellular carcinoma","volume":"24","author":"Alkharashi","year":"2023","journal-title":"Am J Case Rep"},{"key":"R30-20250527","doi-asserted-by":"crossref","first-page":"e0005","DOI":"10.1097\/coa.0000000000000005","article-title":"Corneal melt associated with cancer immunotherapy","volume":"2","author":"Hsu","year":"2023","journal-title":"Cornea Open"},{"key":"R31-20250527","doi-asserted-by":"crossref","first-page":"102283","DOI":"10.1016\/j.coi.2023.102283","article-title":"Immune checkpoint receptors in autoimmunity","volume":"80","author":"Burke","year":"2023","journal-title":"Curr Opin Immunol"},{"key":"R32-20250527","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jtos.2021.02.004","article-title":"Ocular surface disease associated with immune checkpoint inhibitor therapy","volume":"20","author":"Park","year":"2021","journal-title":"Ocular Surf"},{"key":"R33-20250527","first-page":"220","article-title":"Effectiveness of topical insulin for the treatment of surface corneal pathologies","volume":"98","author":"Mora","year":"2023","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"R34-20250527","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jaad.2019.07.005","article-title":"Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review","volume":"82","author":"Fisher","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"R35-20250527","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","article-title":"Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma","volume":"27","author":"Spain","year":"2016","journal-title":"Ann Oncol"},{"key":"R36-20250527","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.survophthal.2007.04.008","article-title":"Corneal graft rejection","volume":"52","author":"Pandaa","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"R37-20250527","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CJI.0000000000000180","article-title":"Immune checkpoint inhibitors in organ transplant patients","volume":"40","author":"Kittai","year":"2017","journal-title":"J Immunother"},{"key":"R38-20250527","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1634\/theoncologist.2018-0195","article-title":"Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue","volume":"24","author":"Aguirre","year":"2019","journal-title":"The oncologist"},{"key":"R39-20250527","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1097\/ICO.0000000000002372","article-title":"Bilateral corneal graft rejection associated with pembrolizumab treatment","volume":"39","author":"Vanhonsebrouck","year":"2020","journal-title":"Cornea"},{"key":"R40-20250527","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"R41-20250527","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/jcp.21635","article-title":"The epidermal growth factor receptor ligands at a glance","volume":"218","author":"Schneider","year":"2009","journal-title":"J Cell Physiol"},{"key":"R42-20250527","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1016\/S0021-9258(19)38983-5","article-title":"Epidermal growth factor","volume":"265","author":"Carpenter","year":"1990","journal-title":"J Biol Chem"},{"key":"R43-20250527","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/107327480701400313","article-title":"EGFR targeting of solid tumors","volume":"14","author":"Rocha-Lima","year":"2007","journal-title":"Cancer Control"},{"key":"R44-20250527","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev.med.55.091902.104433","article-title":"The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors","volume":"55","author":"Rowinsky","year":"2004","journal-title":"Annu Rev Med"},{"key":"R45-20250527","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1179\/ACB.66.1.2062508","article-title":"Epidermal growth factor receptor targeted therapies for solid tumours","volume":"66","author":"Van den Eynde","year":"2011","journal-title":"Acta Clinica Belgica"},{"key":"R46-20250527","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1006\/exer.2000.0979","article-title":"The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis","volume":"72","author":"Nakamura","year":"2001","journal-title":"Exp Eye Res"},{"key":"R47-20250527","first-page":"505","article-title":"The EGF receptor \u2013 an essential regulator of multiple epidermal functions","volume":"10","author":"Jost","year":"2000","journal-title":"Eur J Dermatol"},{"key":"R48-20250527","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/BF00918846","article-title":"Distribution of epidermal growth factor in rat ocular and periocular tissues","volume":"231","author":"Watanabe","year":"1993","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R49-20250527","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/02841860310006038","article-title":"Epidermal growth factor receptor inhibition induces trichomegaly","volume":"42","author":"Dueland","year":"2003","journal-title":"Acta Oncol"},{"key":"R50-20250527","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00520-012-1645-y","article-title":"Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review","volume":"21","author":"Borkar","year":"2013","journal-title":"Support Care Cancer"},{"key":"R51-20250527","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/15569527.2011.636118","article-title":"Trichomegaly and other external eye side effects associated with epidermal growth factor","volume":"31","author":"Fraunfelder","year":"2012","journal-title":"Cutan Ocul Toxicol"},{"key":"R52-20250527","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/ICO.0b013e31818fdbc6","article-title":"Persistent corneal epithelial defect associated with erlotinib treatment","volume":"28","author":"Johnson","year":"2009","journal-title":"Cornea"},{"key":"R53-20250527","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000358082","article-title":"Spontaneous healing of corneal perforation after temporary discontinuation of erlotinib treatment","volume":"5","author":"Morishige","year":"2014","journal-title":"Case Rep Ophthalmol"},{"key":"R54-20250527","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/ICO.0b013e318166f483","article-title":"Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody)","volume":"27","author":"Foerster","year":"2008","journal-title":"Cornea"},{"key":"R55-20250527","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1200\/JCO.2011.35.0694","article-title":"Human epidermal growth factor eyedrops for cetuximab-related filamentary keratitis","volume":"29","author":"Kawakami","year":"2011","journal-title":"J Clin Oncol"},{"key":"R56-20250527","first-page":"379132","article-title":"Perforating corneal ulceration in a patient with lung metastatic adenocarcinoma treated with gefitinib: a case report","volume":"2012","author":"Ibrahim","year":"2012","journal-title":"Case Rep Ophthalmol Med"},{"key":"R57-20250527","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/ICO.0b013e318064584a","article-title":"Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature","volume":"26","author":"Zhang","year":"2007","journal-title":"Cornea"},{"key":"R58-20250527","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"R59-20250527","first-page":"1","article-title":"Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective","volume":"12","author":"Lacouture","year":"2007","journal-title":"Skin Therapy Letter"},{"key":"R60-20250527","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1610-0387.2005.05058.x","article-title":"The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies: Behandlung der Hautreaktionen bei EGFR-spezifischer Tumortherapie (Epidermaler Wachstumsfaktor Rezeptor)","volume":"3","author":"Segaert","year":"2005","journal-title":"J Deutschen Dermatol Gesellschaft"},{"key":"R61-20250527","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann Oncol"},{"key":"R62-20250527","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/annonc\/mdj084","article-title":"Cetuximab and irinotecan\/5-fluorouracil\/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma","volume":"17","author":"Folprecht","year":"2006","journal-title":"Ann Oncol"},{"key":"R63-20250527","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","article-title":"Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225","volume":"144","author":"Busam","year":"2001","journal-title":"Br J Dermatol"},{"key":"R64-20250527","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1159\/000088502","article-title":"Cetuximab-induced acne","volume":"211","author":"Molinari","year":"2005","journal-title":"Dermatology"},{"key":"R65-20250527","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/annonc\/mdi300","article-title":"Trichomegaly of the eyelashes following treatment with cetuximab","volume":"16","author":"Bouche","year":"2005","journal-title":"Ann Oncol"},{"key":"R66-20250527","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1067\/mjd.2002.124621","article-title":"Paronychia induced by cetuximab, an antiepidermal growth factor receptor antibody","volume":"47","author":"Boucher","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R67-20250527","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","article-title":"Dermatologic side effects associated with the epidermal growth factor receptor inhibitors","volume":"55","author":"Agero","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"R68-20250527","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3816\/CCC.2008.n.005","article-title":"Epidermal growth factor receptor inhibitor\u2013related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker","volume":"7","author":"Bianchini","year":"2008","journal-title":"Clin Colorectal Cancer"},{"key":"R69-20250527","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2004.06026.x","article-title":"Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours","volume":"151","author":"Jacot","year":"2004","journal-title":"Br J Dermatol"},{"key":"R70-20250527","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1097\/01.NCC.0000281758.85704.9b","article-title":"Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer","volume":"30","author":"Lacouture","year":"2007","journal-title":"Cancer Nurs"},{"key":"R71-20250527","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/IOP.0b013e31802d97f0","article-title":"Newly recognized ocular side effects of erlotinib","volume":"23","author":"Methvin","year":"2007","journal-title":"Ophthal Plast Reconstruct Surg"},{"key":"R72-20250527","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000514696","article-title":"Bilateral severe corneal ulcer in a patient with lung adenocarcinoma treated with gefitinib","volume":"12","author":"Gozzi","year":"2021","journal-title":"Case Rep Ophthalmol"},{"key":"R73-20250527","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/ICO.0000000000001808","article-title":"Bilateral ulcerative keratitis associated with afatinib treatment for non\u2013small-cell lung carcinoma","volume":"38","author":"Mckelvie","year":"2019","journal-title":"Cornea"},{"key":"R74-20250527","first-page":"bcr0120091473","article-title":"A case of acquired trichomegaly following treatment with erlotinib","volume":"2009","author":"Jazayeri","year":"2009","journal-title":"Case Rep"},{"key":"R75-20250527","doi-asserted-by":"crossref","first-page":"1104.e1","DOI":"10.1016\/j.ophtha.2012.12.025","article-title":"Erlotinib-related corneal melting","volume":"120","author":"Chow","year":"2013","journal-title":"Ophthalmology"},{"key":"R76-20250527","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1016\/j.ophtha.2012.03.002","article-title":"Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases","volume":"119","author":"Saint-Jean","year":"2012","journal-title":"Ophthalmology"},{"key":"R77-20250527","doi-asserted-by":"crossref","first-page":"100630","DOI":"10.1016\/j.ajoc.2020.100630","article-title":"Rapidly progressive streptococcus dysgalactiae corneal ulceration associated with erlotinib use in stage IV lung cancer","volume":"18","author":"Sobol","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R78-20250527","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jfo.2018.07.005","article-title":"Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): a prospective trial","volume":"41","author":"Saint-Jean","year":"2018","journal-title":"J Fran\u00e7ais Ophtalmol"},{"key":"R79-20250527","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/S1470-2045(18)30520-5","article-title":"Tyrosine kinase inhibitor-induced corneal ulcers","volume":"20","author":"Ka Wai","year":"2019","journal-title":"Lancet Oncol"},{"key":"R80-20250527","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/sj.eye.6701630","article-title":"Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (\u2018Iressa\u2019, ZD1839) in Phase I and II clinical trials","volume":"19","author":"Tullo","year":"2005","journal-title":"Eye"},{"issue":"(S202)","key":"R81-20250527","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1755-3768.1992.tb02170.x","article-title":"Effects of growth factors on corneal wound healing","volume":"70","author":"Schultz","year":"1992","journal-title":"Acta Ophthalmol"},{"key":"R82-20250527","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00055735-199608000-00002","article-title":"Extracellular matrix and growth factors in corneal wound healing","volume":"7","author":"Nishida","year":"1996","journal-title":"Curr Opin Ophthalmol"},{"key":"R83-20250527","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jamaophthalmol.2023.6089","article-title":"Epidermal growth factor receptor inhibitors for lung cancer and the risk of keratitis","volume":"142","author":"Huang","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R84-20250527","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jtos.2024.03.008","article-title":"New-onset keratitis associated with epidermal growth factor receptor-based targeted therapies in Han Chinese patients with lung cancer: a multicenter cohort study","volume":"33","author":"Ma","year":"2024","journal-title":"Ocul Surf"},{"key":"R86-20250527","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/OTT.S54606","article-title":"Ocular side effects of biological agents in oncology: what should the clinician be aware of?","volume":"7","author":"Hager","year":"2013","journal-title":"OncoTargets Ther"},{"key":"R87-20250527","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/eye.2017.222","article-title":"Neuro-ophthalmic side effects of molecularly targeted cancer drugs","volume":"32","author":"Bhatti","year":"2018","journal-title":"Eye"}],"container-title":["Current Opinion in Allergy &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000001007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T18:09:04Z","timestamp":1748369344000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ACI.0000000000001007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":86,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0000000000001007","relation":{},"ISSN":["1528-4050","1473-6322"],"issn-type":[{"value":"1528-4050","type":"print"},{"value":"1473-6322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]}}}